Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMA2IXQ)

Drug Name
GSK2586184 Drug Info
Synonyms GSK-2586184
Indication
Disease Entry ICD 11 Status REF
Systemic lupus erythematosus 4A40.0 Phase 2 [1]
Arthritis FA20 Phase 1 [2]
Cross-matching ID
PubChem CID
44603362
CAS Number
CAS 1206163-45-2
TTD Drug ID
DMA2IXQ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 1 (JAK-1) DTT JAK1 8.621 9.012 9.168 8.535
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Systemic lupus erythematosus
ICD Disease Classification 4A40.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Janus kinase 1 (JAK-1) DTT JAK1 6.35E-07 -0.28 -1.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01777256) An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01336244) GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study. U.S. National Institutes of Health.
3 DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9.